[Perioperative management of lung cancer patients with cardiovascular complications].

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: Nankodo Country of Publication: Japan NLM ID: 0413533 Publication Model: Print Cited Medium: Print ISSN: 0021-5252 (Print) Linking ISSN: 00215252 NLM ISO Abbreviation: Kyobu Geka Subsets: MEDLINE
    • Publication Information:
      Publication: Tokyo : Nankodo
      Original Publication: Tokyo.
    • Subject Terms:
      Perioperative Care*; Cardiovascular Diseases/*complications ; Fibrinolytic Agents/*administration & dosage ; Heparin/*administration & dosage ; Heparin, Low-Molecular-Weight/*administration & dosage ; Lung Neoplasms/*complications ; Lung Neoplasms/*surgery ; Postoperative Complications/*prevention & control; Aged ; Female ; Humans ; Male ; Mesenteric Artery, Superior ; Middle Aged ; Pneumonectomy ; Pulmonary Embolism/prevention & control ; Venous Thromboembolism/prevention & control
    • Abstract:
      Lung cancer patients with cardiovascular complications often require antithrombotic therapy. In this study, we discuss the present conditions and future problems associated with the perioperative management of such patients. We examined 36 lung cancer patients undergoing surgery who received antithrombotic therapy for cardiovascular complications. Twenty-one patients were administered unfractionated heparin in the perioperative period (heparin group). Fifteen patients were not administered unfractionated heparin in the perioperative period (no-heparin group). No significant intergroup differences were observed in operating time, intraoperative blood loss, duration of chest tube placement, and the number of hospitalization days. However, 2 serious cases of thromboembolism developed after surgery. One was a case of pulmonary thromboembolism and the other was one of superior mesenteric artery thromboembolism. These results suggest that the appropriate perioperative usage of heparin enables the standard surgical treatment of lung cancer patients with cardiovascular complications. We recommend the use of low-molecular-weight heparin or low-dose unfractionated heparin as the antithrombotic agent after lung cancer surgery.
    • Accession Number:
      0 (Fibrinolytic Agents)
      0 (Heparin, Low-Molecular-Weight)
      9005-49-6 (Heparin)
    • Publication Date:
      Date Created: 20150404 Date Completed: 20150918 Latest Revision: 20150403
    • Publication Date:
      20240829
    • Accession Number:
      25836997